India's Sun Pharma falls after US FDA indicates official action for Baska facility

Shares of Sun Pharmaceutical Industries SUN.NS fall 2.8% to 1,742.70 rupees

U.S. FDA classified co's Baska facility as "Official Action Indicated" after inspection

Classification means regulatory or administrative actions are recommended

"This is an important facility for co's injectable generic filings in U.S. and new product approvals from this facility can be delayed substantially," Citi says

SUN says it continues to manufacture and supply approved products from Baska facility to U.S. market

Adds, co will work to achieve fully compliant status

Citi says classification poses risk of a negative impact on FY27 estimates for SUN's U.S. generic sales and EPS

YTD, SUN down around 7% vs Nifty Pharma index's .NIPHARM nearly 4% fall